ホーム>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Cyclizine

Cyclizine

カタログ番号GC64088

Products are for research use only. Not for human use. We do not sell to patients.

Cyclizine 化学構造

Cas No.: 82-92-8

サイズ 価格 在庫数 個数
10 mg
$351.00
在庫あり
25 mg
$567.00
在庫あり
50 mg
$945.00
在庫あり
100 mg
$1,512.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Cyclizine, a piperazine-derivative, is a potent and selective histamine H1 receptor antagonist. Cyclizine can be used for the research of nausea, vomiting, and dizziness[1][2][3].

Cyclizine (100 μM) significantly inhibits nitrite accumulation and iNOS protein levels in the LPS-stimulated in RAW 264.7 cells supernatants[1].Cyclizine inhibits anti-IgE-induced histamine release from isolated human lung fragments, with an IC50 of 5.42 µM[2].

Cyclizine (1, 10 mg/kg) enhances locomotor activity of mice in a dose-dependent manner[3].

[1]. KrÁlovÁ J, et, al. The effects of H1-antihistamines on the nitric oxide production by RAW 264.7 cells with respect to their lipophilicity. Int Immunopharmacol. 2009 Jul;9(7-8):990-5.
[2]. Church MK, et, al. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol. 1980 Aug;69(4):663-7.
[3]. Leza JC, et, al. Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity. Gen Pharmacol. 1991;22(2):293-6.

レビュー

Review for Cyclizine

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cyclizine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.